510(k) Report

510(k) · Cleared

Cleared

Glucoleader Value

K023279510(k) TraditionalCleared Aug 4, 2003307-day reviewClass II21 CFR 862.1345

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Hmd Biomedical, Inc. · NBW System, Test, Blood Glucose, Over The Counter

Cleared on Aug 4, 2003 after a 307-day review. FDA’s file for it is a 510(k) statement, which names no predicate. 8 later devices descend from it.

Decided
Aug 4, 2003
Review
307 days
Class
Class II
Product code
NBW
Recalls
None
Predicates
0

8 later devices descend from it, 1 citing it directly.

Descendants, by year cleared 2003: 1 descendant cleared2019: 1 descendant cleared2012: 3 descendants cleared2015: 1 descendant cleared2014: 1 descendant cleared2022: 1 descendant cleared200020052010201520202025
  1. This deviceK023279 Glucoleader ValueHmd Biomedical, Inc. · 2003
  2. Descendant · cites it directly · 7 of its ownK032985 Glucoleader Enhance Self-Monitoring of Blood Glucose SystemHmd Biomedical, Inc. · 2003
  3. Descendant · 2 generations on · 1 of its ownK182428 GlucoLeader Enhance Blood Glucose Monitoring SystemHmd Biomedical, Inc. · 2019
  4. Descendant · 2 generations on · 1 of its ownK120064 Test, Blood Glucose SystemHmd Biomedical, Inc. · 2012
  5. Descendant · 2 generations on · 1 of its ownK113307 GL Goodlife Series Blood Glucose Monitoring SysmtemHmd Biomedical, Inc. · 2012
  6. Descendant · 3 generations on · 0 of its ownK212248 GlucoLeader Enhance 2 Blood Glucose Monitoring SystemHmd Biomedical, Inc. · 2022

Showing 5 of 8 descendants. See all descendants

Descendants cleared per year

2003: 12012: 32014: 12015: 12019: 12022: 1
2003high 3 (2012) · low 0 (2004)2026

Most influential descendants

Showing 5 of 8 · See all
  • K032985Glucoleader Enhance Self-Monitoring of Blood Glucose SystemHmd Biomedical, Inc. · 2003 · cites it directly7descendants
  • K182428GlucoLeader Enhance Blood Glucose Monitoring SystemHmd Biomedical, Inc. · 2019 · 2 generations on1descendant
  • K120064Test, Blood Glucose SystemHmd Biomedical, Inc. · 2012 · 2 generations on1descendant
  • K113307GL Goodlife Series Blood Glucose Monitoring SysmtemHmd Biomedical, Inc. · 2012 · 2 generations on1descendant
  • K212248GlucoLeader Enhance 2 Blood Glucose Monitoring SystemHmd Biomedical, Inc. · 2022 · 3 generations on0descendants
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
0 (this device)K023279Glucoleader ValueHmd Biomedical, Inc.2003—
+1K032985Glucoleader Enhance Self-Monitoring of Blood Glucose SystemHmd Biomedical, Inc.2003—
+2K182428GlucoLeader Enhance Blood Glucose Monitoring SystemHmd Biomedical, Inc.2019—
+2K120064Test, Blood Glucose SystemHmd Biomedical, Inc.2012—
+2K113307GL Goodlife Series Blood Glucose Monitoring SysmtemHmd Biomedical, Inc.2012—
+3K212248GlucoLeader Enhance 2 Blood Glucose Monitoring SystemHmd Biomedical, Inc.2022—

Descendants by year cleared

Year clearedDevicesWith a Class I recall
200310
201230
201410
201510
201910
202210
FIG. 1 — Lineage of K023279, 2003–2022Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA 510(k) statement (indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in NBW? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new NBW device

  1. #1 K260545 CONTOUR® PLUS BLUE Blood Glucose Monitoring…score 14.6 · 10 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against?

FDA’s file for it is a 510(k) statement, which names no predicate.

What descends from it? (8)

1 later device cites it directly; ranked here by how many devices descend from each in turn.

NumberDeviceApplicantDecidedDescendants
K032985Glucoleader Enhance Self-Monitoring of Blood Glucose SystemHmd Biomedical, Inc.20037

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • Of its descendants, K032985 (Hmd Biomedical, Inc., 2003) has gone furthest, with 7 descendants of its own.

How does its category compare?

All NBW devices

NBW System, Test, Blood Glucose, Over The Counter: FDA decisions, review times, recalls and adverse event reports over 20 years.

FDA decisions per year · NBW

2in 2025

2007: 292008: 372009: 382010: 312011: 302012: 302013: 472014: 242015: 322016: 202017: 252018: 192019: 102020: 72021: 72022: 122023: 52024: 72025: 22026 (partial year): 5
2007high 47 (2013) · low 2 (2025)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · NBW

243in 2024

2007: 85 days median2008: 128 days median2009: 140 days median2010: 132 days median2011: 328 days median2012: 230 days median2013: 167 days median2014: 202 days median2015: 237 days median2016: 233 days median2017: 244 days median2018: 168 days median2019: 127 days median2020: 121 days median2021: 465 days median2022: 410 days median2023: 193 days median2024: 243 days median2026 (partial year): 190 days median
2007high 465 (2021) · low 85 (2007)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · NBW

1in 2025

2007: 92008: 22009: 52010: 112011: 12012: 12013: 5, 2 Class I2014: 12016: 12019: 142025: 1
2007high 14 (2019) · low 0 (2015)2026

Class I (2 since 2007) Class II/III not classified

Adverse event reports per year · NBW

4,745in 2025

2007: 7,9912008: 7,7042009: 10,9632010: 11,6312011: 22,9092012: 23,4492013: 35,4082014: 38,5242015: 62,1112016: 76,6212017: 37,5382018: 16,9112019: 14,4722020: 10,7032021: 9,1982022: 8,1032023: 7,2562024: 6,2202025: 4,745
2007high 76,621 (2016) · low 4,745 (2025)2025

MAUDE reports naming product code NBW, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
2007298597,991
20083712827,704
200938140510,963
2010311321111,631
201130328122,909
201230230123,449
2013471675 (2)35,408
201424202138,524
201532237062,111
201620233176,621
201725244037,538
201819168016,911
2019101271414,472
20207121010,703
2021746509,198
20221241008,103
2023519307,256
2024724306,220
20252—14,745
202651900—

What is it indicated for?

For the quantitative measurement of glucose levels in human capillary whole blood. For use in personal self monitoring and by health care workers in a professional setting.

Indications for use as stated in the FDA 510(k) statement.

Cite this page

510(k) Report. “K023279: Glucoleader Value.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 4, 2026. https://510kreport.com/device/K023279

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026